Lithium, a common drug for bipolar disorder treatment, regulates amyloid-β precursor protein processing

Yuan Su, John Ryder, Baolin Li, Xin Wu, Niles Fox, Pat Solenberg, Kellie Brune, Steven Paul, Yan Zhou, Feng Liu, Binhui Ni

Research output: Contribution to journalArticlepeer-review

283 Scopus citations

Abstract

Lithium is one of the most widely used mood-stabilizing agents for the treatment of bipolar disorder. Although the underlying mechanism(s) of this mood stabilizer remains controversial, recent evidence linking lithium to neurotrophic/neuroprotective effects (Choi and Sung (2000) 1475, 225-230; Davies et al. (2000) 351, 95-105) suggests novel benefits of this drug in addition to mood stabilization. Here, we report that both lithium as well as valproic acid (VPA) inhibit β-amyloid peptide (Aβ) production in HEK293 cells stably transfected with Swedish amyloid precursor protein (APP)751 and in the brains of the PDAPP (APPV717F) Alzheimer's disease transgenic mouse model at clinically relevant plasma concentrations. Both lithium and VPA are known to be glycogen synthase kinase-3 (GSK3) inhibitors. Our studies reveal that GSK3β is a potential downstream kinase, which modulates APP processing because inhibition of GSK3 activity by either a dominant negative GSK3β kinase-deficient construct or GSK3β antisense oligonucleotide mimics lithium and VPA effects. Moreover, lithium treatment abolished GSK3β-mediated Aβ increase in the brains of GSK3β transgenics and reduced plaque burden in the brains of the PDAPP (APPV717F) transgenic mice.

Original languageEnglish
Pages (from-to)6899-6908
Number of pages10
JournalBiochemistry
Volume43
Issue number22
DOIs
StatePublished - Jun 8 2004

Fingerprint

Dive into the research topics of 'Lithium, a common drug for bipolar disorder treatment, regulates amyloid-β precursor protein processing'. Together they form a unique fingerprint.

Cite this